These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30803948)

  • 1. Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study.
    Vilar-Gomez E; Athinarayanan SJ; Adams RN; Hallberg SJ; Bhanpuri NH; McKenzie AL; Campbell WW; McCarter JP; Phinney SD; Volek JS; Chalasani N
    BMJ Open; 2019 Feb; 9(2):e023597. PubMed ID: 30803948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study.
    Hallberg SJ; McKenzie AL; Williams PT; Bhanpuri NH; Peters AL; Campbell WW; Hazbun TL; Volk BM; McCarter JP; Phinney SD; Volek JS
    Diabetes Ther; 2018 Apr; 9(2):583-612. PubMed ID: 29417495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study.
    Bhanpuri NH; Hallberg SJ; Williams PT; McKenzie AL; Ballard KD; Campbell WW; McCarter JP; Phinney SD; Volek JS
    Cardiovasc Diabetol; 2018 May; 17(1):56. PubMed ID: 29712560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in patient-reported sleep in type 2 diabetes and prediabetes participants receiving a continuous care intervention with nutritional ketosis.
    Siegmann MJ; Athinarayanan SJ; Hallberg SJ; McKenzie AL; Bhanpuri NH; Campbell WW; McCarter JP; Phinney SD; Volek JS; Van Dort CJ
    Sleep Med; 2019 Mar; 55():92-99. PubMed ID: 30772699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver Fat Scores Moderately Reflect Interventional Changes in Liver Fat Content by a Low-Fat Diet but Not by a Low-Carb Diet.
    Kabisch S; Bäther S; Dambeck U; Kemper M; Gerbracht C; Honsek C; Sachno A; Pfeiffer AFH
    Nutrients; 2018 Jan; 10(2):. PubMed ID: 29385034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 8. Noninvasive Liver Fibrosis Indices as Indicators of Microvascular and Macrovascular Complications in Type 2 Diabetes.
    Erman H; Boyuk B; Arslan S; Akin S; Keskin Ö
    Metab Syndr Relat Disord; 2024 Oct; 22(8):619-625. PubMed ID: 38836748
    [No Abstract]   [Full Text] [Related]  

  • 9. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.
    Mantovani A; Sani E; Fassio A; Colecchia A; Viapiana O; Gatti D; Idolazzi L; Rossini M; Salvagno G; Lippi G; Zoppini G; Byrne CD; Bonora E; Targher G
    Diabetes Metab; 2019 Sep; 45(4):347-355. PubMed ID: 30315891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
    World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers.
    Mazzotti A; Caletti MT; Brodosi L; Di Domizio S; Forchielli ML; Petta S; Bugianesi E; Bianchi G; Marchesini G
    J Hepatol; 2018 Nov; 69(5):1155-1163. PubMed ID: 30290973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD.
    Welsh JA; Scorletti E; Clough GF; Englyst NA; Byrne CD
    J Leukoc Biol; 2018 Sep; 104(3):631-639. PubMed ID: 29603349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes.
    Wang N; Wang Y; Zhang W; Chen Y; Chen X; Wang C; Li Q; Chen C; Jiang B; Lu Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3210. PubMed ID: 31351021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
    Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nonalcoholic Fatty Liver Disease Fibrosis Score Is Related to Epicardial Fat Thickness and Complexity of Coronary Artery Disease.
    Turan Y
    Angiology; 2020 Jan; 71(1):77-82. PubMed ID: 31018673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of the specialised blood fibrosis tests FibroMeter
    Guillaume M; Moal V; Delabaudiere C; Zuberbuhler F; Robic MA; Lannes A; Metivier S; Oberti F; Gourdy P; Fouchard-Hubert I; Selves J; Michalak S; Peron JM; Cales P; Bureau C; Boursier J
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1214-1222. PubMed ID: 31617224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.